Welcome to BioSeeker Group!

Targeted Therapeutics in Non-Small Cell Lung Cancer

Additional Information

Published Date Apr 26, 2007
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 282
PDF Fact Sheet View Fact Sheet for the report Targeted Therapeutics in Non-Small Cell Lung Cancer in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

With this report you will be able to track down and foresee activities associated with the development of new treatments for NSCLC.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Targeted Therapeutics in Non-Small Cell Lung Cancer.

    To find out more about Targeted Therapeutics in Non-Small Cell Lung Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Targeted Therapeutics in Non-Small Cell Lung Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Introduction

Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for non-small cell lung cancer (NSCLC): cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. New data on platinum-based chemotherapy has been presented. Both Avastin and Efaproxyn have generated additional data.

In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 22 late stage drug candidates are described and analysed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for NSCLC and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine).

Example of drugs included in this study

Affinitak, Aptosyn, Bevacizumab, Carboxyamidotriazole, Cetuximab, CI-994, Docetaxel, Efaproxyn, Erlotinib, Gefitinib, Gemcitabine, Genasense, Lapatinib IGN-101, Mitumomab, Neovastat, Paclitaxel, Panitumumab, Pemetrexed, Targretin, Telcyta, Tirapazamine, Trastuzumab, Vinflunine, Vinorelbine, Xcytrin, ZD-6474,

Example of companies included in this study

Abgenix, Aphton, AstraZeneca, Bristol-Myers Squibb, Cell Pathways, Eli Lilly, Genentech, Genta, GlaxoSmithKline, ImClone, ISIS Pharmaceuticals, Ligand Pharmaceuticals, OSI Pharmaceuticals, Pfizer, Pharmacyclics, Sanofi-Aventis, Telik

Scope of this report

Thorough examination of status and impact of many novel drugs in development
Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
Case studies on major lung cancer drugs on market and in development.

Key reasons to read this report

  • Explore the strengths and weaknesses associated with compounds in clinical development.
  • Scientific rationale for novel therapeutics in lung cancer, and the results of clinical trials to date.
  • Gain insight into the current challenges and commercial opportunities associated with lung cancer

 

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 4.1 List of boxes
4.2 List of tables
4.3 Appendices

5 Introduction
5.1 Current Treatment Strategies
5.2 Disease Definition
5.3 Etiology & Pathophysiology
5.4 Prognosis
5.5 Epidemiology

6 Progress in current treatment strategies
6.1 Docetaxel
6.2 Vinorelbine
6.3 Gemcitabine
6.4 Paclitaxel
6.5 Pemetrexed
6.6 Gefitinib
6.7 Erlotinib
6.8 Bevacizumab

7 Key Therapeutic Strategies
7.1 Apoptosis
7.2 Protein Kinase Inhibition - Antiangiogenesis and Antivascular Agents
7.2.1 EGFR and VEGFR as target
7.3 Immunotherapy

8 Competitive Landscape in NSCLC Drug Development: The Late Stage Pipeline
8.1 Protein Kinase Inhibitors
8.2 Apoptotic Inducers
8.3 Immunotherapy
8.4 Other Therapeutic Strategies

9 Disclaimer
9.1 Liability
9.2 Completeness

10 Appendix 1. Treatment Guide Lines

11 Appendix 2 Progress Profiles on Approved Drugs
11.1 Docetaxel
11.2 Vinorelbine
11.3 Gemcitabine
11.4 Paclitaxel
11.5 Pemetrexed
11.6 Gefitinib
11.7 Erlotinib

12 Drug Index

13 Company Index

4.1 List of boxes

Box 1: Quick Facts - Docetaxel
Box 2: Scientific Data on Docetaxel
Box 3: Quick Facts – Vinorelbine
Box 4: Scientific Data on Vinorelbine
Box 5: Quick Facts – Gemcitabine
Box 6: Scientific Data on gemcitabine
Box 7: The PIONEER clinical trial
Box 8: Quick Facts – Pemetrexed
Box 9: Scientific Data on Pemetrexed
Box 10: Quick Facts – Gefitinib
Box 11: Scientific Data on Gefitinib
Box 12: Expert comment
Box 13: Quick Facts – Erlotinib

4.2 List of tables

Table 1: Chemotherapeutic Drugs for Treatment of NSCLC
Table 2: Clinical Studies of NSCLC Patients With EGFR Mutations
Table 3 Progress on Bevacizumab
Table 4. Near Term Approved Drugs for the Treatment of NSCLC
Table 5: Chemotherapy Drugs off Patent
Table 6 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
Table 7 VTA Agents Under Development
Table 8 EGFR or VEGFR Inhibitors
Table 9: FMS-Like Tyrosine Kinases and Their Synonyms
Table 10: Fms-related Tyrosine Kinase Targets in Development
Table 11: Protein Kinase Targets in Clinical Trials for Lung Cancer
Table 12 Cancer Immunotherapy Strategies
Table 13 Progress on Lapatinib
Table 14 Progress on ZD6474
Table 15: Progress on Trastuzumab
Table 16 Progress on Panitumumab
Table 17 Progress on Cetuximab
Table 18: Progress on Neovastat
Table 19: Progress on Affinitak
Table 20: Progress on Sorafenib
Table 21: Progress on Canfosfamide
Table 22: Progress on Exisulind
Table 23 Progress on Genasense
Table 24 Progress on Bexarotene
Table 25: Progress on IGN101
Table 26: Progress on CPG 7909
Table 27 Progress on Vinflunine
Table 28: Progress on Talabostat
Table 29: Ongoing Studies
Table 30 Progress on Xcytrin
Table 31: Progress on Tirapazamine
Table 32: Progress on Efaproxiral

4.3 Appendices
10 Appendix 1. Treatment Guide Lines
11 Appendix 2 Progress Profiles on Approved Drugs

- Abgenix
- Aphton
- AstraZeneca
- Bristol-Myers Squibb
- Cell Pathways
- Eli Lilly
- Genentech
- Genta
- GlaxoSmithKline
- ImClone
- ISIS Pharmaceuticals
- Ligand Pharmaceuticals
- OSI Pharmaceuticals
- Pfizer
- Pharmacyclics
- Sanofi-Aventis
- Telik

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Targeted Therapeutics in Non-Small Cell Lung Cancer.
    To find out more about Targeted Therapeutics in Non-Small Cell Lung Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Targeted Therapeutics in Non-Small Cell Lung Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place
This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market. Learn More


Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
This report will excel your competitive awareness and decrease your decision making time in managing apoptotic drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Learn More


Commercial Interests at ASGCT 2017 - A 1stOncology Insights Report
The Commercial Interests at ASGCT 2017 report is a must have companion tool for reviewing the direction of commercial drug development emerging from the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2017. Learn More